Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2CNS 1

Conditions

Meningioma 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Pituitary Neoplasms 1Paraganglioma 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Brain Neoplasms 1Acromegaly 1

Interventions

Proton Therapy 2pegvisomant 1lutetium Lu 177 dotatate 1entinostat 1Temozolomide 1Surveys and Questionnaires 1Rosiglitazone 1Radiation Dose Hypofractionation 1Protons 1Prednisone 1Photochemotherapy 1Octreotide 1Neuropsychological Tests 1Microarray Analysis 1Hydrocortisone 1Dihematoporphyrin Ether 1Dexamethasone 1DNA Methylation 1Clinical Laboratory Techniques 1Calcium Dobesilate 1Cabergoline 1Blood Specimen Collection 1Aminolevulinic Acid 190Y-octreotide, DOTA-Tyr(3)- 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × Octreotide × CNS × Clear all
NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡